TScan Therapeutics, Inc.

As of July 1, 2025, TScan Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, including a mildly bullish weekly MACD but a bearish monthly outlook, and has significantly underperformed the S&P 500 with a year-to-date return of -43.42%.

As of November 10, 2021, TScan Therapeutics, Inc. is considered risky and overvalued due to significant losses and unfavorable valuation ratios, with a year-to-date return of -43.42%, indicating that the market may not be adequately pricing in its financial risks.

As of November 10, 2021, TScan Therapeutics, Inc. is classified as "risky" and overvalued, with unfavorable financial metrics including a Price to Book Value of 0.48, an EV to EBIT of 0.81, an EV to EBITDA of 0.83, and a concerning -62.03% return on equity, alongside a year-to-date stock performance of -52.3% compared to a 2.44% return for the S&P 500.

As of May 27, 2025, TScan Therapeutics, Inc. exhibits a mildly bearish trend, with mixed signals from key indicators like MACD, RSI, and Bollinger Bands suggesting weak bearish sentiment in the market.

TScan Therapeutics, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, reporting net sales of $2 million and a net loss of $34 million as of March 2025. Key financial metrics include a market cap of $87.15 million, a negative P/E ratio, and a return on equity of -62.03%.

As of Jun 18, TScan Therapeutics, Inc. has a market capitalization of 87.15 million, with net sales of 4.43 million and a net profit of -131.49 million over the last four quarters. The company reported shareholder's funds of 240.97 million and total assets of 371.12 million as of Dec 24.